Dacomitinib as a First‐Line Therapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer Without Brain Metastases: A Multicenter Retrospective Observational Study

ABSTRACT Background Real‐world evidence regarding the use of dacomitinib as a first‐line therapy for advanced non‐small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations remains limited. This multicenter, retrospective cohort study aimed to evaluate the clinical outcome...

詳細記述

書誌詳細

主要な著者:	Ping‐Chih Hsu, How‐Wen Ko, Li‐Chung Chiu, Shih‐Hao Huang, Chung‐Shu Lee, Yu‐Ching Lin, Scott Chih‐Hsi Kuo, Jia‐Shiuan Ju, Chin‐Chou Wang, Cheng‐Ta Yang
フォーマット:	Artigo
言語:	Inglês
出版事項:	Wiley 2026-03-01
シリーズ:	Cancer Medicine
主題:	common EGFR mutation dacomitinib epidermal growth factor receptor mutation non‐small cell lung cancer (NSCLC) tyrosine kinase inhibitor
オンライン･アクセス:	https://doi.org/10.1002/cam4.71659
タグ:	タグ追加 タグなし, このレコードへの初めてのタグを付けませんか!